Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-001 in advanced B-cell malignancies
NCT03424603Phase 1Completed
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Feb 2018
- Primary completion
- Feb 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of STRO-001 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Sutro Biopharma, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Recommended Phase 2 Dose and Maximum Tolerated Dose at 18 months and 1 more. Started Feb 2018; status: completed.
02
Drugs
STRO-001
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03424603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424603.